trb_welcome.jpg

 

The mission of TRB Chemedica Group is to develop innovative and patented pharmaceutical products and medical devices in niche therapeutic areas: rheumatology, ophthalmology and neurology.


Video on Dry Eyeeye_pic.jpg

In recent years the nosology of Dry Eye has greatly changed. Professor Baudouin, MD, PhD from National Ophthalmologiy Hospital XV-XX, Vision Institute of Paris explains through this didactic video the complexity of the Dry Eye disease. Moving beyond the simple name of Dry Eye syndrome, we now consider the condition to be Dry Eye disease, insisting on the lack of tears, the lacrimal inflammation and hyperevaporation leading to self-sustaining loops of neurogenic and palpebral inflammations.

View the video


ostenil_ptit.png

Restoring Synovial Balance

OSTENIL® is a solution containing hyaluronic acid for injection into the joint cavity.

OSTENIL® is indicated for the treatment of symptoms of osteoarthritis. It has been shown to reduce pain and stiffness in the affected joint and to improve joint function.

A treatment cycle of 3 to 5 injections of OSTENIL®  results in a decrease in joint pain and an improvement in joint function which may last for several months.

OSTENIL® is designed for long-term symptomatic relief in osteoarthritis.

ostenil.jpg

pdfOSTENIL® instructions for use
trb_lock.gif Doctor information
Distributors
trb_contact.gifContacts

News-Events
 
 
  • English